Circulating CD34 Positive Cells and Immunological Responses in Extremely Preterm Infants.

IF 2.1 Q3 HEMATOLOGY
Journal of Blood Medicine Pub Date : 2025-10-22 eCollection Date: 2025-01-01 DOI:10.2147/JBM.S541742
Ulrika Sjöbom, Helena Barreto Henriksson, Anders K Nilsson, Pia Lundgren, Karin Sävman, Ann Knattan Hellström, Sofia Frändberg
{"title":"Circulating CD34 Positive Cells and Immunological Responses in Extremely Preterm Infants.","authors":"Ulrika Sjöbom, Helena Barreto Henriksson, Anders K Nilsson, Pia Lundgren, Karin Sävman, Ann Knattan Hellström, Sofia Frändberg","doi":"10.2147/JBM.S541742","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The dynamic changes of the hematopoietic system during fetal development may be disrupted by preterm birth. Hematopoietic stem and progenitor cell (CD34<sup>+</sup>) levels are poorly investigated in preterm infants, particularly in relation to immune responses and morbidities. This is partly because of low blood volumes, which raise ethical concerns and limit specific sampling for research studies. To overcome this problem, we used residual blood from routine clinical testing to monitor CD34<sup>+</sup> cell counts in the first months of life. Our aim was to characterize the dynamics of circulating CD34<sup>+</sup> cells and explore associations with prenatal and postnatal clinical events.</p><p><strong>Methods: </strong>We retrieved residual blood samples from nine infants born <28 weeks gestational age (GA), collected from birth through eight postnatal weeks. CD34<sup>+</sup> cell count was assessed using flow cytometry. The number of nucleated red and white blood cells, and hemoglobin concentration were also measured.</p><p><strong>Results: </strong>Median (min-max) GA was 25+0 (22+3─27+5) weeks. CD34<sup>+</sup> cell counts at birth ranged from 19 to 284 x 10<sup>6</sup> cells/L. Between days 0 and 1, CD34<sup>+</sup> cell count increased in four infants and decreased in four. By day 7, the proportion of CD34<sup>+</sup> of total nucleated blood cells was significantly lower than at birth (p=0.018). High inter- and intra-individual variability in CD34<sup>+</sup> cell count was observed. Notably, the highest CD34<sup>+</sup> cell levels coincided with maternal or infant infections.</p><p><strong>Conclusion: </strong>This pilot study demonstrates the feasibility of longitudinal monitoring of CD34<sup>+</sup> hematopoietic stem and progenitor cells in extremely preterm infants using residual clinical blood samples. While limited by a small sample size, the study provides preliminary insights into early immune function and highlights directions for future research in larger cohorts.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"16 ","pages":"483-492"},"PeriodicalIF":2.1000,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12554276/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Blood Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/JBM.S541742","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The dynamic changes of the hematopoietic system during fetal development may be disrupted by preterm birth. Hematopoietic stem and progenitor cell (CD34+) levels are poorly investigated in preterm infants, particularly in relation to immune responses and morbidities. This is partly because of low blood volumes, which raise ethical concerns and limit specific sampling for research studies. To overcome this problem, we used residual blood from routine clinical testing to monitor CD34+ cell counts in the first months of life. Our aim was to characterize the dynamics of circulating CD34+ cells and explore associations with prenatal and postnatal clinical events.

Methods: We retrieved residual blood samples from nine infants born <28 weeks gestational age (GA), collected from birth through eight postnatal weeks. CD34+ cell count was assessed using flow cytometry. The number of nucleated red and white blood cells, and hemoglobin concentration were also measured.

Results: Median (min-max) GA was 25+0 (22+3─27+5) weeks. CD34+ cell counts at birth ranged from 19 to 284 x 106 cells/L. Between days 0 and 1, CD34+ cell count increased in four infants and decreased in four. By day 7, the proportion of CD34+ of total nucleated blood cells was significantly lower than at birth (p=0.018). High inter- and intra-individual variability in CD34+ cell count was observed. Notably, the highest CD34+ cell levels coincided with maternal or infant infections.

Conclusion: This pilot study demonstrates the feasibility of longitudinal monitoring of CD34+ hematopoietic stem and progenitor cells in extremely preterm infants using residual clinical blood samples. While limited by a small sample size, the study provides preliminary insights into early immune function and highlights directions for future research in larger cohorts.

Abstract Image

Abstract Image

循环CD34阳性细胞和极早产儿的免疫反应
背景:胎儿发育过程中造血系统的动态变化可能因早产而中断。造血干细胞和祖细胞(CD34+)水平在早产儿中的研究很少,特别是在免疫反应和发病率方面。部分原因是血容量低,这引起了伦理问题,并限制了研究的特定采样。为了克服这个问题,我们使用常规临床检测的残血来监测生命最初几个月的CD34+细胞计数。我们的目的是表征循环CD34+细胞的动力学特征,并探讨其与产前和产后临床事件的关系。方法:收集9例新生儿的残血样本,用流式细胞术检测细胞计数。同时测定有核红细胞和白细胞的数量及血红蛋白浓度。结果:GA中位数(min-max)为25+0(22+3─27+5)周。出生时CD34+细胞计数为19 ~ 284 × 106细胞/L。从第0天到第1天,4名婴儿的CD34+细胞计数增加,4名婴儿的CD34+细胞计数减少。第7天时,总有核血细胞中CD34+的比例显著低于出生时(p=0.018)。观察到CD34+细胞计数的高个体间和个体内变异性。值得注意的是,最高的CD34+细胞水平与母亲或婴儿感染一致。结论:本初步研究证实了利用临床剩余血液样本对极早产儿CD34+造血干细胞和祖细胞进行纵向监测的可行性。虽然受限于小样本量,但该研究为早期免疫功能提供了初步见解,并为未来更大规模的研究指明了方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.50
自引率
0.00%
发文量
94
审稿时长
16 weeks
期刊介绍: The Journal of Blood Medicine is an international, peer-reviewed, open access, online journal publishing laboratory, experimental and clinical aspects of all topics pertaining to blood based medicine including but not limited to: Transfusion Medicine (blood components, stem cell transplantation, apheresis, gene based therapeutics), Blood collection, Donor issues, Transmittable diseases, and Blood banking logistics, Immunohematology, Artificial and alternative blood based therapeutics, Hematology including disorders/pathology related to leukocytes/immunology, red cells, platelets and hemostasis, Biotechnology/nanotechnology of blood related medicine, Legal aspects of blood medicine, Historical perspectives. Original research, short reports, reviews, case reports and commentaries are invited.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书